Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.32 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.32 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL290841 | 0.97 | TDP1 (0.53) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL4807582 | 0.91 | TSHR (0.41) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL9655437 | 0.90 | TSHR (0.45) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL8356836 | 0.87 | TDP1 (0.43) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL3508428 | 0.87 | TSHR (0.43) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL9655441 | 0.85 | TSHR (0.41) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Toluene SCHEMBL536968 | 0.85 | TSHR (0.44) | TDP1TSHRNAPRTCHRNB2CHRNA4 | |
| Pyridine SCHEMBL11393043 | 0.84 | TSHR (0.39) | TDP1TSHRNAPRTHTTKDM4E | |
| Pyrazine SCHEMBL28358879 | 0.82 | HRH3 (0.32) | TDP1CHRNB2CHRNA4HTTKDM4E | |
| Pyridine SCHEMBL15019090 | 0.82 | KCNH2 (0.41) | TDP1TSHRNAPRTCHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1173193-A4 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | UNIV PRINCETON (US) | 2003-01-29 | — | — | EP | claimed |
| EP-1173193-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | The Trustees of Princeton University (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000059528-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-10-12 | — | — | WO | claimed |
| US-8673885-B1 | Compounds for the protection of sulfur containing linkers in nucleic acid synthesis | DUFF ROBERT (US) | 2014-03-18 | — | — | US | disclosed |
| US-7482444-B2 | Terminating substrates for DNA polymerases | WALLAC OY (FI) | 2009-01-27 | — | — | US | disclosed |
| US-20070248973-A1 | Terminating substrates for DNA polymerases | WALLAC OY (FI) | 2007-10-25 | — | — | US | disclosed |
| WO-2007104834-A1 | TERMINATING SUBSTRATES FOR DNA POLYMERASES | WALLAC OY (FI) | 2007-09-20 | — | — | WO | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| EP-1173193-A4 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | UNIV PRINCETON (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-0830365-B1 | MODIFIED KOJIBIOSIDES ANALOGUES | ALBERTA RES COUNCIL (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-4518532-A | ANTITIMOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-21 | — | — | US | disclosed |
| EP-0119448-A1 | Oligonucleotide derivatives and production thereof | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1984-09-26 | — | — | EP | disclosed |
| US-4430346-A | N-(4-(3-AMINOPROPYL)AMINOBUTYL)-2-(CS)-7-GUANIDINO-3 -HYDROXYHEPTANAMIDE)-2-HYDROXYETHANAMIDE, ESTERS, AMIDATION ACID CATALYST | BRISTOL-MYERS COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| US-4170642-A | TREATMENT OF BACTERIAL INFECTIONS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-10-09 | — | — | US | disclosed |
| US-4107424-A | ANTIBACTERIAL | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-08-15 | — | — | US | disclosed |
| US-4001208-A | DERIVATIVE OF AN AMINOGLYCOSIDIC ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYO KAI (JA) | 1977-01-04 | — | — | US | disclosed |
| US-3940382-A | BACTERICIDE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-02-24 | — | — | US | disclosed |
| US-3939143-A | BACTERICIDE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | CHRM2 3763/4885HTR1A 2725/4885ADRA2A 3411/4885 |
| US-20070248973-A1 | Terminating substrates for DNA polymerases | POLN, POLM, POLRMT | CHRM2 4880/4885HTR1A 4797/4885ADRA2A 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.